Stone House Investment Management’s Beam Therapeutics BEAM Stock Holding History

Stone House Investment Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$309	Buy	+9	New	+$272	﹤0.01%	1119

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Stone House Investment Management's BEAM Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 9 shares worth $309. The stake represents ﹤0.01% of the portfolio and ranks #1119 among its holdings.

277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Stone House Investment Management held 9 shares of Beam Therapeutics worth $309 as of Q2 2026.
Beam Therapeutics was a new Stone House Investment Management position in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1119 holding.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.